Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06373146 · ClinicalTrials.gov registry record · Phase 2
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
A Phase 2 study of Obesity, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 392
- Enrollment target
- 17
- Study locations
NCT06373146: Active Phase 2 study of Obesity, sponsored by Eli Lilly and Company.
NCT06373146 is a Phase 2 study of Obesity that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 392 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (52% lower). The trial reports 17 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06373146, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 392 participants
- Enrollment target
- 17
- Study locations
Study Summary
The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Mibavademab
- DRUG Tirzepatide-Placebo
- DRUG Mibavademab-Placebo
Study Locations (17)
California
- Velocity Clinical Research, Gardena - Gardena
- Irvine Clinical Research - Irvine
- Velocity Clinical Research, Los Angeles - Los Angeles
- Velocity Clinical Research, North Hollywood - North Hollywood
- Velocity Clinical Research, Santa Ana - Santa Ana
- Velocity Clinical Research, Panorama City - Van Nuys
- Diablo Clinical Research, Inc. - Walnut Creek
Texas
- South Texas Clinical Research - Corpus Christi
- Velocity Clinical Research, Dallas - Dallas
- Juno Research - Houston
Louisiana
- Tandem Clinical Research - Marrero
- Velocity Clinical Research - New Orleans - New Orleans
Idaho
- Solaris Clinical Research - Meridian
New Jersey
- Hassman Research Institute Marlton Site - Marlton
North Dakota
- Lillestol Research - Fargo
Ohio
- CTI Clinical Research Center - Cincinnati
Washington
- Northwest Clinical Research Center - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2024-04-24 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What the registry record for NCT06373146 still lists
NCT06373146 is an interventional study that assigns participants to a tested intervention. The registered 392 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Tirzepatide is the first listed.
NCT06373146 lists 17 locations in 8 states (California, Texas, Louisiana).
Frequently Asked Questions
What is clinical trial NCT06373146 about?
NCT06373146 is a clinical study titled "A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity". The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
What is the current status of trial NCT06373146?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 392 participants. The study started on 2024-04-24. Estimated completion is 2026-04.
What conditions does trial NCT06373146 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06373146?
The interventions under investigation include: Tirzepatide (DRUG), Mibavademab (DRUG), Tirzepatide-Placebo (DRUG), Mibavademab-Placebo (DRUG).
Who is sponsoring clinical trial NCT06373146?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06373146 being conducted?
This trial has 17 study locations across California, Idaho, Louisiana, New Jersey, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06373146's enrollment target sits among peer trials
392 174th of 1053 higher than 879 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI